Drugs / MAD0004J08
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04932850 | Mar → Oct 2021 | COVID-19 | Toscana Life Sciences Sviluppo s.r.l. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04952805 | Jun 2021 → Mar 2022 | COVID-19 | Toscana Life Sciences Sviluppo s.r.l. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAD0004J08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04932850 ↗ |
| Action | Inhibit | “MAD0004J08 blocks viral attachment and entry into human cells and neutralizes the virus.” NCT04952805 ↗ |
| Modality | Monoclonal antibody | “a new monoclonal antibody (called MAD0004J08)” NCT04932850 ↗ |
| Route | Intramuscular | “Administration occurs as intramuscular injection” NCT04932850 ↗ |